SCHEMBL7473692

SCHEMBL7473692

COc1ccc(N2C[C@H](CN3CCC(Cc4ccc(F)cc4)CC3)OC2=O)cc1

nearest known ligand 0.66

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 16/20 0.66
CCR3 P51677 4/20 0.52
CCR5 P51681 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7528602 0.92 SIGMAR1 (0.53) SIGMAR1
SCHEMBL7484241 0.91 SIGMAR1 (0.59) SIGMAR1
SCHEMBL9678853 0.90 SIGMAR1 (0.65) SIGMAR1
Hydrochloric Acid SCHEMBL10389069 0.89 SIGMAR1 (0.64) SIGMAR1
SCHEMBL7488795 0.88 SIGMAR1 (0.50) SIGMAR1
SCHEMBL7470276 0.87 SIGMAR1 (0.52) SIGMAR1
SCHEMBL7468890 0.87 SIGMAR1 (0.52) SIGMAR1
SCHEMBL9676204 0.87 GRM2 (0.57) SIGMAR1
SCHEMBL7470797 0.86 SIGMAR1 (0.50) SIGMAR1
SCHEMBL8799384 0.86 SIGMAR1 (0.68) SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0763535-B1 Piperidinylmethyloxazolidin-2-one derivatives, their preparation and their use as pharmacological active CNS compounds MERCK PATENT GMBH (DE) 2002-11-27 EP claimed
EP-0763535-A1 Piperidinylmethyloxazolidin-2-one derivatives, their preparation and their use as pharmacological active CNS compounds MERCK PATENT GmbH (DE) 1997-03-19 EP claimed
EP-0763535-B1 Piperidinylmethyloxazolidin-2-one derivatives, their preparation and their use as pharmacological active CNS compounds MERCK PATENT GMBH (DE) 2002-11-27 EP disclosed
US-6413989-B1 5-(4-(4-FLUOROBENZYL)PIPERIDIN-1-YLMETHYL)-3-(4-HYDROXYPHENYL) OXAZOLIDIN-2-ONE NEUROLEPTIC AGENT MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2002-07-02 US disclosed
US-20020061912-A1 PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2002-05-23 US disclosed
EP-1015447-B1 PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE MERCK PATENT GMBH (DE) 2002-04-10 EP disclosed
EP-1015447-A1 PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE MERCK PATENT GmbH (DE) 2000-07-05 EP disclosed
WO-1999012924-A1 PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE MERCK PATENT GMBH (DE) 1999-03-18 WO disclosed
EP-0763535-A1 Piperidinylmethyloxazolidin-2-one derivatives, their preparation and their use as pharmacological active CNS compounds MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061912-A1 PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE GRIN2C, GRIN1, GRIN2D SIGMAR1 135/4885CCR3 4804/4885CCR5 3690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.